Generic Name: (Human Menopusal Gonadotropin)
Each vial of lyophilized product HMG Massone 75 IU contains:
Follicle Stimulating Hormone (FSH): 75 I.U.
Luteinizing Hormone (LH): 75 I.U.
Lactose: 20 mg.
Each ampoule of solvent contains:
Sodium chloride injection (USP) 0.85% / 1 ml.
Therapeutical action: HMG Massone 75 is a follicle and luteinic hormonal association, in which the follicle stimulating action prevails.
Indications: Women: Ovulatory disorders or anovulatory infertility. Wrong follicle maturation with consequences on the corpus luteum development. Ovulation induction in assisted reproductive treatments.
For Women the administration of HMG Massone 75 for 7 to 12 days causes follicle development and maturation in those patients with no early ovarian failure. To trigger ovulation, Human Chrionic Gonadotrophin (HCG) is administered after HMG administration.
For Men the administration of HMG Massone 75 for at least three months together with Human Chorionic Gonadotropin (HCG) induces spermatogenesis in men with primary or secondary pituitary hypofunction who were able to reach proper masculinization through previous HCG treatment.
Posology: Proper HMG Massone 75 dose to stimulate the ovarian follicles is unique for each patient. Based on the clinical experience and data available, the lower dose with which good results can be obtained should be used.
The HMG Massone 75 advisable initial dose is of 150 I.U. daily for the first five days of treatment. Based on the clinical monitoring the subsequent dose should be determined according to the response. Dose adjustments should not be more frequent than one adjustment every 2 days, and not more than 75 to 150 I.U. should be used per adjustment.
HMG Massone 75 maximum daily dose should not be higher than 450 I.U. and a dosage regimen beyond twelve days is not advisable.
Keep below 25 ºC. Keep preferably refrigerated between 2 - 8 ºC.
Keep away from children.